OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
|Articles|May 1, 2002
- Pharmaceutical Technology-05-02-2002
- Volume 26
- Issue 5
Polymers in Transdermal Drug Delivery Systems
Author(s)Ramesh Panchagnula, PhD
Recent advances in polymer science have resulted in a wide range of commercially available polymers for use in transdermal drug delivery systems.
Advertisement
Articles in this issue
over 24 years ago
Harmonizing Standards and Specificationsover 24 years ago
Expanding the Use of Child-Resistant Packagingover 24 years ago
Outsourcing Outlookover 24 years ago
E-Procurement — Reverse Auctions and the Supplier's PerspectiveAdvertisement
Related to this article
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Germany’s Medical Biotechnology Sector is Flourishing
3
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5